Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 1/20 | 0.48 |
| ▸ | ECE1 | P42892 | 1/20 | 0.48 |
| ▸ | CTSS | P25774 | 5/20 | 0.48 |
| ▸ | CTSL | P07711 | 4/20 | 0.48 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.46 |
| ▸ | CAPN2 | P17655 | 1/20 | 0.46 |
| ▸ | CTSB | P07858 | 3/20 | 0.46 |
| ▸ | CTSK | P43235 | 2/20 | 0.46 |
| ▸ | SIRT2 | Q8IXJ6 | 4/20 | 0.45 |
| ▸ | SIRT1 | Q96EB6 | 2/20 | 0.45 |
| ▸ | SIRT3 | Q9NTG7 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | CA12 | O43570 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | CA4 | P22748 | 1/20 | 0.45 |
| ▸ | CA9 | Q16790 | 1/20 | 0.45 |
| ▸ | TLR2 | O60603 | 1/20 | 0.44 |
| ▸ | CASP1 | P29466 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12335557 | 1.00 | MME (0.48) | MMEECE1CTSSCTSLCAPN1 | |
| SCHEMBL14433709 | 0.84 | CTSS (0.58) | MMEECE1CTSSCTSLCTSB | |
| SCHEMBL13884485 | 0.84 | CTSS (0.58) | MMEECE1CTSSCTSLCTSB | |
| SCHEMBL1122463 | 0.84 | CTSS (0.58) | MMEECE1CTSSCTSLCTSB | |
| SCHEMBL8496964 | 0.83 | SMN1; SMN2 (0.61) | MMEECE1CTSSCTSLCTSB | |
| SCHEMBL36611 | 0.83 | SMN1; SMN2 (0.61) | MMEECE1CTSSCTSLCTSB | |
| SCHEMBL13671074 | 0.82 | CTSS (0.50) | MMEECE1CTSSCTSLCAPN1 | |
| SCHEMBL757049 | 0.82 | CTSS (0.50) | MMEECE1CTSSCTSLCAPN1 | |
| SCHEMBL12109818 | 0.82 | SMN1; SMN2 (0.54) | MMEECE1CTSSCTSLCTSB | |
| Hydroxyamine SCHEMBL9197242 | 0.82 | SMN1; SMN2 (0.60) | MMEECE1CTSSCTSLCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2842576-B1 | Transglutaminase mediated conjugation of peptides | NOVO NORDISK HEALTHCARE AG (CH) | 2017-06-28 | — | — | EP | disclosed |
| US-20160355859-A1 | TRANSGLUTAMINASE MEDIATED CONJUGATION OF PEPTIDES | NOVO NORDISK A/S (DK) | 2016-12-08 | — | — | US | disclosed |
| CN-103215328-B | The joint of transglutaminase mediated peptide | 诺和诺德医疗保健公司 | 2016-08-03 | — | — | CN | disclosed |
| CN-1909930-B | Transglutaminase mediated conjugation of peptides | NOVO NORDISK HEALTH CARE AG (CH) | 2015-12-16 | — | — | CN | disclosed |
| EP-2842576-A1 | Transglutaminase mediated conjugation of peptides | Novo Nordisk Health Care AG (CH) | 2015-03-04 | — | — | EP | disclosed |
| EP-2033662-B1 | Transglutaminase mediated conjugation of peptides | NOVO NORDISK HEALTHCARE AG (CH) | 2012-10-17 | — | — | EP | disclosed |
| EP-1708755-B1 | TRANSGLUTAMINASE MEDIATED CONJUGATION OF PEPTIDES | NOVO NORDISK HEALTHCARE AG (CH) | 2012-03-21 | — | — | EP | disclosed |
| EP-2368579-A1 | Transglutaminase mediated conjugation of peptides | Novo Nordisk Health Care AG (CH) | 2011-09-28 | — | — | EP | disclosed |
| US-20090264366-A1 | Transglutaminase Mediated Conjugation of Peptides | NOVO NORDISK HEALTHCARE AG (CH) | 2009-10-22 | — | — | US | disclosed |
| EP-2033662-A1 | Transglutaminase mediated conjugation of peptides | Novo Nordisk Health Care AG (CH) | 2009-03-11 | — | — | EP | disclosed |
| US-20070105770-A1 | Transglutaminase mediated conjugation of peptides | NOVO NORDISK A/S (DK) | 2007-05-10 | — | — | US | disclosed |
| EP-1708755-A2 | TRANSGLUTAMINASE MEDIATED CONJUGATION OF PEPTIDES | NOVO NORDISK A/S (DK) | 2006-10-11 | — | — | EP | disclosed |
| WO-2005070468-A2 | TRANSGLUTAMINASE MEDIATED CONJUGATION OF PEPTIDES | NOVO NORDISK A/S (DK) | 2005-08-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264366-A1 | Transglutaminase Mediated Conjugation of Peptides | TGM2, TGM3, TGM1 | MME 405/4885ECE1 575/4885CTSS 629/4885 |
| US-20070105770-A1 | Transglutaminase mediated conjugation of peptides | TGM2, TGM3, TGM1 | MME 405/4885ECE1 575/4885CTSS 629/4885 |
| US-20160355859-A1 | TRANSGLUTAMINASE MEDIATED CONJUGATION OF PEPTIDES | TGM2, TGM3, TGM1 | MME 405/4885ECE1 575/4885CTSS 629/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.